Dexcom, Inc. announced that coverage for Dexcom G6 rtCGM System on the Non-Insured Health Benefits (NIHB) Program has been expanded to include all clients living with type 1 diabetes. This announcement expands upon coverage already in place for clients aged 2 to 19 on intensive insulin therapy, giving even more First Nations and Inuit people access to this standard of care, potentially helping them to have more control over a life-long chronic illness. Dexcom rtCGM use is proven to improve glycemic control1,2 and can reduce the risk of costly long-term diabetes-related complications.3 As part of the NIHB coverage program, clients aged 2 to 19 on intensive insulin therapy AND clients of all ages with type 1 diabetes can now obtain their Dexcom G6 rtCGM supplies directly from their local pharmacy.

Dexcom G6 uses a small, wearable sensor and transmitter to continuously measure and send glucose levels wirelessly to a smart device* or receiver, giving patients real-time glucose data without the need to scan or prick their finger routinely.† The system has customizable and predictive alerts and alarms to help avoid potentially dangerous low and high blood sugar events and a function that allows patients to share their glucose data in real time with up to 10 followers. Dexcom G6 also offers connectivity through integrations with leading insulin delivery systems and digital health apps.